Urgent interim commissioning policy: Peginterferon alfa-2a and ropeginterferon alfa-2b to treat myeloproliferative neoplasms

Document first published:
Page updated:
Topic:
Publication type:

NHS England has confirmed that peginterferon alfa-2a and ropeginterferon alfa-2b will be made available as treatment options for people with myeloproliferative neoplasms (MPNs) within the criteria set out in this urgent interim commissioning policy position during the period of supply disruption of peginterferon alfa-2a which is expected to be until July 2025.

Document

Urgent interim commissioning policy: Peginterferon alfa-2a and ropeginterferon alfa-2b to treat myeloproliferative neoplasms

Urgent interim commissioning policy: Peginterferon alfa-2a and ropeginterferon alfa-2b to treat myeloproliferative neoplasms

  • PDF
  • 208 KB
  • 10 pages

Summary

Urgent interim commissioning policy.

Document

Equality and health inequalities impact assessment (EHIA): Peginterferon alfa-2a and ropeginterferon alfa-2b to treat myeloproliferative neoplasms

Equality and health inequalities impact assessment (EHIA): Peginterferon alfa-2a and ropeginterferon alfa-2b to treat myeloproliferative neoplasms

  • PDF
  • 135 KB
  • 12 pages

Summary

Equality and health inequalities impact assessment (EHIA).

Document

Three paper summary: a) Peginterferon alfa-2 and ropeginterferon alfa-2b to treat myeloproliferative neoplasms (myelofibrosis)

Three paper summary: a) Peginterferon alfa-2 and ropeginterferon alfa-2b to treat myeloproliferative neoplasms (myelofibrosis)

  • PDF
  • 173 KB
  • 6 pages

Document

Three paper summary: b) Peginterferon alfa-2 and ropeginterferon alfa-2b to treat myeloproliferative neoplasms (polycythaemia vera)

Three paper summary: b) Peginterferon alfa-2 and ropeginterferon alfa-2b to treat myeloproliferative neoplasms (polycythaemia vera)

  • PDF
  • 285 KB
  • 14 pages

Document

Three paper summary: c) Peginterferon alfa-2 and ropeginterferon alfa-2b to treat myeloproliferative neoplasms (essential thrombocythaemia)

Three paper summary: c) Peginterferon alfa-2 and ropeginterferon alfa-2b to treat myeloproliferative neoplasms (essential thrombocythaemia)

  • PDF
  • 252 KB
  • 12 pages

Document

Three paper summary: d) Peginterferon alfa-2 and ropeginterferon alfa-2b to treat myeloproliferative neoplasms (polycythaemia vera)

Three paper summary: d) Peginterferon alfa-2 and ropeginterferon alfa-2b to treat myeloproliferative neoplasms (polycythaemia vera)

  • PDF
  • 256 KB
  • 13 pages